High penetration drugs and their compositions thereof for treatment of parkinson diseases

作者: Lina Xu , Chongxi Yu

DOI:

关键词: ProdrugPharmacologyDrug metabolismPenetration (firestop)ChemistryGeneral Circulation Model

摘要: One aspect of the invention provides a composition novel high penetration compositions (HPC) or prodrug (HPP) for treatment Parkinson's disease. The HPCs/HPPs are capable being converted to parent active drugs drug metabolites after crossing biological barrier and thus can render treatments conditions that can. Additionally, HPPs reaching areas may not be able access sufficient concentration at target therefore treatments. administered subject through various administration routes, e.g., locally delivered an action site condition with systematically enter general circulation faster rate.

参考文章(21)
Nicholas S. Bodor, Stefano A. Pogany, Kenneth B. Sloan, Novel dopa/dopamine prodrugs ,(1980)
Steven J. Siegel, Terri B. Sebree, Implants for the treatment of dopamine associated states ,(2007)
Jia-Ning Xiang, Cindy X. Zhou, Fenmei Yao, Mark Q. Nguyen, Catechol protected levodopa diester prodrugs, compositions, and methods of use ,(2007)
Ada Rephaeli, Abraham Weizman, Gideon Stein, Abraham Nudelman, Irit Gil-Ad, Novel conjugates for treating neurodegenerative diseases and disorders ,(2009)
Anwar A. Hussain, Kenneth B. Sloan, Nicolae S. Bodor, Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease ,(1975)
Jose A Obeso, Maria Cruz Rodríguez‐Oroz, Beatriz Benitez‐Temino, Franscisco J Blesa, Jorge Guridi, Concepció Marin, Manuel Rodriguez, None, Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease Movement Disorders. ,vol. 23, ,(2008) , 10.1002/MDS.22062
Nicholas Bodor, Kenneth B. Sloan, Takeru Higuchi, Kunihiro Sasahara, Improved delivery through biological membranes. 4. Prodrugs of L-dopa. Journal of Medicinal Chemistry. ,vol. 20, pp. 1435- 1445 ,(1977) , 10.1021/JM00221A014